Tyrosine Kinase Inhibitors: all 10,469 studies that test it

Page 19 of 105. Open to participants first (1,907), then studies with results posted, then the rest; newest registration first within each.

• Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic TreatmentRecruitingNCT04333108Phase 3
• Neoadjuvant SHR-1210 Plus Apatinib for Resectable Stage III-IV Acral MelanomaRecruitingNCT04331093Phase 2
• Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic MutationRecruitingNCT04322890Phase 2
• Anlotinib Plus Immune Checkpoint Inhibitors for Lung CancerRecruitingNCT04322617Phase 2/3
• Crizotinb or Standard Chemotherapy in Met Exon 14 Skipping Advanced NSCLCRecruitingNCT04322578Phase 2
• Lenvatinib Following Liver Transplantation in Patients of Hepatocellular Carcinoma With Portal Vein Tumor ThrombusNot yet recruitingNCT04319484Phase 2/3
• A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic LeukaemiaRecruitingNCT04307576Phase 3
• Study of Trametinib and Ruxolitinib in Colorectal Cancer and Pancreatic AdenocarcinomaRecruitingNCT04303403Phase 1
• A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)RecruitingNCT04302025Phase 2
• A Study of Fluzoparib±Apatinib Versus Chemotherapy Treatment of Physician's Choice in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA MutationRecruitingNCT04296370Phase 3
• A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 MutationsRecruitingNCT04293562Phase 3
• Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative NeoplasmsRecruitingNCT04282187Phase 2
• Anlotinib Plus Toripalimab as First-line Treatment for Advanced Gastric Cancer With ECOG 2 (APICAL-GC)RecruitingNCT04278222Phase 2
• Efficacy and Safety of Zanubrutinib Plus Tislelizumab Treatment With or Without Sonrotoclax for Patients With Richter TransformationRecruitingNCT04271956Phase 2
• Study to Evaluate the Pharmacokinetics (PK) of E7090 (Herein Referred to as Tasurgratinib) and Its Metabolite in Participants With Mild and Moderate Hepatic Impairment Compared to Healthy ParticipantsRecruitingNCT04271488Phase 1
• Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung CancerRecruitingNCT04270591Phase 1/2
• Adjuvant Study of Pyrotinib in HER-2 Positive Breast CancerRecruitingNCT04254263Phase 3
• A Phase I/II Clinical Study of SAF-189s in Non-small Cell Lung Cancer (NSCLC) PatientsRecruitingNCT04237805Phase 1/2
• Cabozantinib to Treat Recurrent Liver Cancer Post TransplantRecruitingNCT04204850Phase 2
• Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent SarcomaRecruitingNCT04199026Not applicable
• A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid TumorRecruitingNCT04192344Phase 1
• Target Therapy With GEMOX in Recectable Gallbladder Carcinoma Patients Monitored by ctDNARecruitingNCT04183712Phase 2
• Erlotinib for Hepatocellular Carcinoma ChemopreventionNot yet recruitingNCT04172779Phase 2
• Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaRecruitingNCT04169737Phase 2
• Adjuvant Dual Anti-HER2 Therapy in Patients With Small, Node-negative, HER2-positive Breast CancerNot yet recruitingNCT04158856Phase 2
• Safety, Tolerability and Pharmacokinetics of Oral CPL304110, in Adult Subjects With Advanced Solid MalignanciesRecruitingNCT04149691Phase 1
• Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative NeoplasmRecruitingNCT04140487Phase 1/2
• A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic AnemiaEnrolling by invitationNCT04138927Phase 3
• Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Osimertinib-resistant Non-squamous NSCLCRecruitingNCT04136535Phase 2
• A Trial to Compare Ibrutinib Versus Lenalidomide in Combination With MRE-chemotherapy for Adult Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL)RecruitingNCT04129710Phase 2
• A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.RecruitingNCT04116541Phase 2
• MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia VeraRecruitingNCT04116502Phase 3
• A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 AlterationsRecruitingNCT04094610Phase 1/2
• A Phase 1 Study of CX1003 (Kanitinib) in Patients with Advanced Solid TumorsRecruitingNCT04093466Phase 1
• Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast CancerRecruitingNCT04090567Phase 2
• MASCT-I Combined With Apatinib and/or Camrelizumab in the Treatment of Bone and Soft Tissue SarcomaRecruitingNCT04074564Early Phase 1
• Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's MacroglobulinaemiaRecruitingNCT04061512Phase 2/3
• Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone SarcomasRecruitingNCT04055220Not applicable
• Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeRecruitingNCT04047641Phase 1/2
• Targeted Pathway Inhibition in Patients With Pancreatic CancerRecruitingNCT04005690Early Phase 1
• Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell LymphomaRecruitingNCT04002947Phase 2
• Clinical Study of Combination Therapy With Ectiecinib, Pemetrexed and Platinum in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer With EGFR Mutations.RecruitingNCT03992885Phase 3
• Adjuvant Chemotherapy With or Without Intercalated IcotinibNot yet recruitingNCT03983811Not applicable
• A Prospective Multicenter Phase 2 Study of FCR/BR Alternating With Ibrutinib in Treatment-naive Patients With CLLRecruitingNCT03980002Phase 2
• Advanced Therapeutics in Rheumatoid Arthritis (RA)RecruitingNCT03976245Phase 4
• A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent GlioblastomaRecruitingNCT03970447Phase 2/3
• Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid TumorsRecruitingNCT03934372Phase 1/2
• APG-2449 in Patients With Advanced Solid TumorsRecruitingNCT03917043Phase 1
• Losartan + Sunitinib in Treatment of OsteosarcomaRecruitingNCT03900793Phase 1
• Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCCRecruitingNCT03899428Phase 2
• Pan Tumor Rollover StudyRecruitingNCT03899155Phase 2
• Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaRecruitingNCT03874052Phase 1
• Acalabrutinib and Venetoclax Treatment of Newly Diagnosed Patients With CLL at High Risk of Infection or Early TreatmentRecruitingNCT03868722Phase 2/3
• Pazopanib for the Treatment of Epistaxis in Hereditary Hemorrhagic TelangiectasiaNot yet recruitingNCT03850730Phase 1/2
• Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid LeukemiaRecruitingNCT03850574Phase 1/2
• Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic DiseaseRecruitingNCT03844360Phase 4
• A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic ArthritisRecruitingNCT03773965Phase 3
• A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets)RecruitingNCT03767075Phase 2
• Examination of Efficacy and Safety of Baricitinib in RA PatientsRecruitingNCT03755466Phase 2
• WIRE - Novel Treatments in Renal Cell CancerRecruitingNCT03741426Phase 2
• Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin LymphomaRecruitingNCT03681561Phase 1/2
• Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic SyndromeRecruitingNCT03661307Phase 1/2
• Study of Anlotinib Combined With Docetaxel in Non-Driver Mutation Non-squamous NSCLC: the Save StudyRecruitingNCT03646968Phase 2
• Combination Chemotherapy With Pazopanib in Children and Adolescents With Relapsed/Refractory Solid TumorsNot yet recruitingNCT03628131Phase 1/2
• ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CMLRecruitingNCT03595917Phase 1
• A Study of HQP1351 in Patients With GIST or Other Solid TumorsRecruitingNCT03594422Phase 1
• Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic LeukemiaRecruitingNCT03571321Phase 1
• VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or LymphomaRecruitingNCT03556228Phase 1/2
• Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal MalignanciesRecruitingNCT03539822Phase 1/2
• Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaRecruitingNCT03516617Phase 2
• Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)RecruitingNCT03486873Phase 3
• A Phase I/II Study of Regorafenib Plus Avelumab in Solid TumorsRecruitingNCT03475953Phase 1/2
• A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIsRecruitingNCT03459534Phase 3
• Treatment of Rheumatoid Arthritis With DMARDs: Predictors of ResponseRecruitingNCT03414502Phase 3
• Gefitinib Combine Radiotherapy as Therapy for Patients With NSCLC Harbouring Sensitive Mutations of EGFRNot yet recruitingNCT03381430Not applicable
• XELOX Plus Apatinib vs XELOX as Post-operative Chemotherapy in Locally Advanced Gastric Signet Ring CarcinomaNot yet recruitingNCT03355612Phase 3
• Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)RecruitingNCT03297606Phase 2
• Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic LeukemiaRecruitingNCT03263572Phase 2
• Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell LymphomaRecruitingNCT03223610Phase 1/2
• Apatinib as the First-Line Therapy in Elderly Locally Advanced or Metastatic Gastric CancerRecruitingNCT03219593Phase 2
• Clinical Trial of Neoadjuvant Targeted Treatment to NSCLC PatientsNot yet recruitingNCT03203590Phase 3
• Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 ChangeRecruitingNCT03191149Phase 2
• APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid TumorsRecruitingNCT03175224Phase 2
• Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS PatientsRecruitingNCT03127267Phase 3
• Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)RecruitingNCT03126916Phase 3
• A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 RearrangementsRecruitingNCT03093116Phase 1/2
• A Clinical Trial With Apatinib for Subjects With Refractory Malignant AscitesRecruitingNCT03020979Phase 2
• Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)RecruitingNCT03016819Phase 3
• Study of Biomarker-Based Treatment of Acute Myeloid LeukemiaRecruitingNCT03013998Phase 2/3
• INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)RecruitingNCT02977780Phase 2
• Study of Ruxolitinib in Relapsed or Refractory T or NK Cell LymphomaRecruitingNCT02974647Phase 2
• The Drug Rediscovery Protocol (DRUP Trial)RecruitingNCT02925234Phase 2
• Study for the Use of TKIs for Treatment of Cognitive Decline Due to Degenerative DementiasEnrolling by invitationNCT02921477Phase 1
• ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell LymphomaRecruitingNCT02858258Phase 3
• Senescence in Chronic Kidney DiseaseEnrolling by invitationNCT02848131Phase 2
• European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory TumorsRecruitingNCT02813135Phase 1/2
• Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaRecruitingNCT02735707Phase 3
• TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage CancerRecruitingNCT02693535Phase 2
• A CpG-methylation-based Assay for Stratifying Stage III Clear Cell Renal Cell Carcinoma of Receiving Adjuvant TreatmentNot yet recruitingNCT02688491Not applicable
• A Phase III Randomized Trial of the Reduction of Chemotherapy in Philadelphia Chromosome-positive ALL of Young AdultsRecruitingNCT02611492Phase 3

← Tyrosine Kinase Inhibitors overview